Date

Monday, 04 April 2011

Location

European Medicines Agency, Amsterdam, the Netherlands

The objective of the meeting is to discuss the clinical development of new drugs for the treatment of chronic hepatitis C in the paediatric population, taking into consideration possible differences between the adult and paediatric population in particular in terms of safety and possibility to extrapolate efficacy from the adult data.

Documents

Share this page